IMMUNOPRECISE ANTIBODIES LTD (IPA) Fundamental Analysis & Valuation

NASDAQ:IPA • CA45257F2008

2.07 USD
+0.14 (+7.25%)
At close: Sep 3, 2025
2.12 USD
+0.05 (+2.42%)
After Hours: 9/3/2025, 8:24:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IPA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IPA. IPA was compared to 57 industry peers in the Life Sciences Tools & Services industry. IPA may be in some trouble as it scores bad on both profitability and health. IPA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. IPA Profitability Analysis

1.1 Basic Checks

  • In the past year IPA has reported negative net income.
  • In the past year IPA has reported a negative cash flow from operations.
  • In the past 5 years IPA always reported negative net income.
  • In the past 5 years IPA always reported negative operating cash flow.
IPA Yearly Net Income VS EBIT VS OCF VS FCFIPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -68.03%, IPA is doing worse than 89.09% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -127.97%, IPA is doing worse than 83.64% of the companies in the same industry.
Industry RankSector Rank
ROA -68.03%
ROE -127.97%
ROIC N/A
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
IPA Yearly ROA, ROE, ROICIPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

  • IPA has a better Gross Margin (55.25%) than 65.45% of its industry peers.
  • IPA's Gross Margin has been stable in the last couple of years.
  • IPA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
IPA Yearly Profit, Operating, Gross MarginsIPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. IPA Health Analysis

2.1 Basic Checks

  • IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IPA has been increased compared to 1 year ago.
  • The number of shares outstanding for IPA has been increased compared to 5 years ago.
  • Compared to 1 year ago, IPA has a worse debt to assets ratio.
IPA Yearly Shares OutstandingIPA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
IPA Yearly Total Debt VS Total AssetsIPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • IPA has an Altman-Z score of -0.35. This is a bad value and indicates that IPA is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.35, IPA is doing worse than 76.36% of the companies in the same industry.
  • A Debt/Equity ratio of 0.49 indicates that IPA is not too dependend on debt financing.
  • IPA has a Debt to Equity ratio of 0.49. This is in the lower half of the industry: IPA underperforms 63.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z -0.35
ROIC/WACCN/A
WACC10.11%
IPA Yearly LT Debt VS Equity VS FCFIPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • IPA has a Current Ratio of 2.08. This indicates that IPA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of IPA (2.08) is comparable to the rest of the industry.
  • IPA has a Quick Ratio of 1.85. This is a normal value and indicates that IPA is financially healthy and should not expect problems in meeting its short term obligations.
  • IPA has a Quick ratio of 1.85. This is comparable to the rest of the industry: IPA outperforms 47.27% of its industry peers.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 1.85
IPA Yearly Current Assets VS Current LiabilitesIPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. IPA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 34.78% over the past year.
  • IPA shows a small growth in Revenue. In the last year, the Revenue has grown by 0.01%.
  • The Revenue has been growing by 11.77% on average over the past years. This is quite good.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%

3.2 Future

  • IPA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.31% yearly.
  • The Revenue is expected to grow by 17.92% on average over the next years. This is quite good.
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPA Yearly Revenue VS EstimatesIPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
IPA Yearly EPS VS EstimatesIPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. IPA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IPA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPA Price Earnings VS Forward Price EarningsIPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPA Per share dataIPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IPA's earnings are expected to grow with 35.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.39%
EPS Next 3Y35.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IPA Dividend Analysis

5.1 Amount

  • No dividends for IPA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

IPA Fundamentals: All Metrics, Ratios and Statistics

IMMUNOPRECISE ANTIBODIES LTD

NASDAQ:IPA (9/3/2025, 8:24:29 PM)

After market: 2.12 +0.05 (+2.42%)

2.07

+0.14 (+7.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)09-11
Earnings (Next)12-08
Inst Owners8.61%
Inst Owner Change11.42%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap95.53M
Revenue(TTM)24.52M
Net Income(TTM)-30.23M
Analysts80
Price Target5.1 (146.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.31%
Min EPS beat(2)0.99%
Max EPS beat(2)87.62%
EPS beat(4)3
Avg EPS beat(4)14.95%
Min EPS beat(4)-35.01%
Max EPS beat(4)87.62%
EPS beat(8)6
Avg EPS beat(8)14.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.96%
Min Revenue beat(2)-12.4%
Max Revenue beat(2)-7.52%
Revenue beat(4)0
Avg Revenue beat(4)-12.13%
Min Revenue beat(4)-22.81%
Max Revenue beat(4)-5.81%
Revenue beat(8)3
Avg Revenue beat(8)-4.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10%
EPS NY rev (1m)-36.36%
EPS NY rev (3m)-36.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.34%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-0.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.4
P/FCF N/A
P/OCF N/A
P/B 5.6
P/tB 9.23
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.38
BVpS0.37
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -68.03%
ROE -127.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.25%
FCFM N/A
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
F-Score4
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 3.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.08
Quick Ratio 1.85
Altman-Z -0.35
F-Score4
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)20.78%
Cap/Depr(5y)25.53%
Cap/Sales(3y)5.4%
Cap/Sales(5y)5.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
EBIT growth 1Y12.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.97%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOPRECISE ANTIBODIES LTD / IPA FAQ

What is the ChartMill fundamental rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IPA.


What is the valuation status for IPA stock?

ChartMill assigns a valuation rating of 1 / 10 to IMMUNOPRECISE ANTIBODIES LTD (IPA). This can be considered as Overvalued.


Can you provide the profitability details for IMMUNOPRECISE ANTIBODIES LTD?

IMMUNOPRECISE ANTIBODIES LTD (IPA) has a profitability rating of 1 / 10.


What is the financial health of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?

The financial health rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) is 2 / 10.